Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  tipifarnib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 67 for your search:
Start Over
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00535, E2902, U10CA180820, U10CA021115, ECOG-E2902, NCT00093470
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004372, NCT00093990
Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003976, R115777-INT-11, JRF-R115777-INT-11, NCT00005648
Tipifarnib in Treating Patients With Myeloproliferative Disorders
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067864, SUMC-NCI-38, NCI-38, 38, NCT00005846
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01442, WSU-C-2679, MAYO-MC0131, NCI-5599, CDR0000331694, MC0131, 5599, N01CM62205, P30CA015083, NCT00070252
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-126, NCT00050986
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 15 to 70
Sponsor: NCI
Protocol IDs: NCI-2012-02862, 2003-0563, 6625, N01CM62202, MDA-2003-0563, NCI-6625, NCT00096122
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00114, CDR0000409695, 2003-0992, 7004, P30CA016672, N01CM17003, N01CM62202, MDA-2003-0992, NCI-7004, NCT00100750
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00676, CDR0000476286, NABTC-05-02, U01CA137443, ABTC-05-02, NCT00335764
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00239, CDR0000543434, 06-12-487, 7868, P30CA013330, N01CM62202, N01CM62204, NYCC-06-12-487, NCT00470301
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-03021, PBTC-014, U01CA081457, NCT00079339
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067632, NYU-9861, JRF-R115777-USA-8B, NCI-G00-1714, NCT00005041
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02335, FCCC-00005, NCI-45, CDR0000067859, 45, NCT00005843
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: FCCC-99031, CDR0000067866, NCI-20, FCC-RRC-56-99, 20, NCT00005848
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067888, NABTC-9901, NCT00005859
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067978, U01CA069912, P30CA015083, 982401, MAYO-982401, NCI-T99-0072, T99-0072, NCT00005989
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MCC-12516, NIH-2030, MCC-12137, MCC-IRB-5442, NCT00012350
Phase II Study of R115777 in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCC-12516, MCC-IRB-6028, NCI-2030, 2030, NCT00021203
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Child
Sponsor: NCI
Protocol IDs: NCI-2012-01861, AAML0122, U10CA098543, CDR0000068788, COG-AAML0122, NCT00025038
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Phase: Phase II
Type: Prevention
Status: Completed
Age: 3 to 25
Sponsor: NCI
Protocol IDs: 010222, 01-C-0222, NCI-01-C-0222, NCI-T99-0090, NCT00029354, T99-0090, NCT00021541
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-02423, RTOG-PA-0020, RTOG-DEV-1003, CDR0000068986, U10CA021661, NCT00026104
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 65 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02980, UMGCC 0116, U01CA069854, U01CA070095, JHOC-J0255, MSGCC-U5400, MSGCC-0116, NCI-1754, 1754, NCT00027872
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03158, J0252, U01CA070095, U01CA069854, JHOC-J0252, MSGCC-0150, NCI-5689, 5689, NCT00045396
Start Over